KEYNOTE-042 5-YEAR SURVIVAL UPDATE: PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, PD-L1POSITIVE, LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER

Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPCASTRO, Gilberto deKUDABA, IvetaWU, Yi-LongLOPES, GilbertoKOWALSKI, Dariusz M.TURNA, Hande Z.CAGLEVIC, ChristianZHANG, LiKARASZEWSKA, BoguslawaLAKTIONOV, Konstantin K.SRIMUNINNIMIT, VichienBONDARENKO, IgorKUBOTA, KaoruMUKHERJEE, RineeLIN, JianxinSOUZA, FabricioMOK, Tony S. K.CHO, Byoung Chul2022-07-222022-07-222021JOURNAL FOR IMMUNOTHERAPY OF CANCER, v.9, suppl.2, p.A390-A390, 2021https://observatorio.fm.usp.br/handle/OPI/47622engopenAccessKEYNOTE-042 5-YEAR SURVIVAL UPDATE: PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, PD-L1POSITIVE, LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCERconferenceObjectCopyright BMJ PUBLISHING GROUP10.1136/jitc-2021-SITC2021.363OncologyImmunology2051-1426